Specifically, the average tumor size of shRNA-GRK3 tumors was reduced as compared to control cells at day 21 (0.86 ± 0.195 cm3 versus 2.32 ± 0.298 cm3, resp., P < 0.05, Figures 5(a) and 5(b)). The gene discussed is GRK3; the disease is neoplasm.